Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
Welvista provides an innovative prescription drug program for residents inSouth Carolina and Texas who fall below 200 percent of the federal povertylevel and are without health insurance coverage. The William E. Murraypharmacy, located at Welvista's headquarters off Forest Drive in Columbia,dispensed more than $34.5 million dollars in prescription medications in 2008to Welvista's patients to treat diabetes, hypertension, mental illness andmore.
Welvista also provides oral healthcare services for the children oflimited income families in South Carolina through Smiles for a Lifetime, withcenters in Allendale County, Dillon II, and Clarendon I and II schooldistricts, and Charleston.
"We are excited to have Takeda as our newest pharmaceutical partner. Wecouldn't exist without our generous partners," says Welvista CEO Ken Trogdon."We are committed to improving health and wellness for the uninsured. Ourmodel has proven its viability and we will continue to add prescription drugsthat we know our patients need."
Welvista is an innovative model of non-governmental healthcareintervention serving thousands of patients in SC and Texas. This healthcarenetwork provides medications at no cost to the uninsured who do not qualifyfor Medicaid, Medicare or VA insurance and those who cannot afford to pay forinsurance coverage on their own. Welvista also operates Smiles, five pediatricdental care centers caring for approximately 3,200 children from limitedincome families who would not otherwise have access to oral healthcare. Withthe addition of Takeda, Welvista now partners with 12 pharmaceutical companiesthat donate prescription drugs to approved patients. To learn more about theorganization, visit www.welvista.org.
About Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Illinois, Takeda Pharmaceuticals North America, Inc.and Takeda Global Research & Development Center, Inc. are subsidiaries ofTakeda Pharmaceutical Company Limited, the largest pharmaceutical company inJapan. The respective companies currently market oral diabetes, insomnia andgastroenterology treatments and seek to bring innovative products to patientsthrough a pipeline that includes compounds in development for diabetes,cardiovascular disease, oncology, gastroenterology, neurology, rheumatologyand other conditions. Takeda is committed to striving toward better healthfor individuals and progress in medicine by developing superior pharmaceuticalproducts. To learn more about these Takeda companies, visit www.tpna.com.
You May Also Like